

ORIGINAL

TSCA NON-CONFIDENTIAL BUSINESS INFORMATION

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8EHQ- 00-14684	89110000163	3/14/11

COMMENTS: COMMUN S (DECLASS)

DOES NOT CONTAIN CBI

RECEIVED
OPPT CBIC

11 MAR 14 PM 12:26



MR # 333864
CONTAINS NO CBI

March 23, 2000

Attention TSCA Section 8(e) coordinator

U.S. Mail Guaranteed Delivery

RECEIPT REQUESTED

Document Control Office (7407)

Room G99 East Tower

Office of Pollution Prevention and Toxics

U.S. ENVIRONMENTAL PROTECTION AGENCY

401 M Street, S.W.

Washington, DC 20460-0001

Certain TSCA Confidential Business Information

Declassified on 3/1/11 for release of chemical identities

Declassified CBI shown in bold

SUBJECT: TSCA 8(e) SUBMISSION (later assigned 8EHO-00-14684 & 88000000123)

Dear Sir or Madam,

is submitting certain data which we believe may be reportable under TSCA 8(e). The information concerns **(RS)-3-allyl-2-methyl-2-4-oxocyclopent-2-enyl 2,2,3,3-tetramethylcyclopropanecarboxylate** () a synthetic pyrethroid insecticide. This chemical is identified by Chemical Abstract number **64742-47-8**. was developed by for use in countries outside the US.

is registered in China and Japan, and obtained EC registration number EINECS **2396512**. is not registered in the US. The toxic findings, which we are reporting below, were known to previously while it was developing this chemical for markets outside the US. These effects only became known to when preparations were made for to import a 500 ml sample of (*End use product name*), from . (*End use product name*) is an insecticidal concentrate containing and other ingredients, as listed below;

1. **(S)-2-methyl-4-oxo-3-(2-propynyl) cyclopent-2-enyl(1R)-cis, trans-chrysanthemate (also known as prallethrin and Etoc®, a registered insecticide - EPA registration number 10308-12)** 25% w/w
2. 50 % w/w
3. mixture of aliphatic hydrocarbons 25% w/w



This sample of (*End use product name*) was imported, solely for R&D testing purposes, on behalf of _____ has no intention of developing (*End use product name*) for use in the United States.

The MSDS for (*End use product name*) lists certain toxicological end points. These end points, and relevant clinical observations from the studies from which these end points were derived, are given below:

Acute oral toxicity; LD₅₀ 518 mg/kg (male rat)
346 mg/kg (female rat)

Clinical observations; tremors, clonic convulsions and tonic convulsions and diarrhea occurred within 30 minutes of administration of the test substance.

Acute dermal; LD₅₀ >2000 mg/kg (male rat)
>2000 mg/kg (female rat)

Clinical observations; none.

Acute inhalation LC₅₀ >200 mg/m³ (male rat)
260 mg/m³ (female rat)

Clinical observations

Rats were exposed to 0, 50, 200 and 400 mg (*End use product name*) /m³. The rats exhibited wet fur, hunched posture, pilo-erection, increased respiratory rate, body tremors, exaggerated sensitivity to external stimuli and vocalization. Rats exposed to the mid and high doses showed ataxia, labored respiration, decreased respiratory rate, high stepping gait, tip toe gait and extension of rear limbs during movement. Surviving animals recovered and appeared to be normal by 2 hours - 2 days of exposure.

We wish to point out that these toxic findings relate to (*End use product name*), rather than to _____ alone. It is therefore not possible to distinguish the toxic effects of the latter active ingredient from those of (*End use product name*) as a whole.

If there are any questions on this submission please feel free to contact me at _____

Yours sincerely,

Encl.